Delivery of the Report will take 2-3 working days once order is placed.
Synopsis
Cancer Janus Kinase Inhibitors
Scope of the Report:
The conventional modes of cancer management including surgery, radiotherapy and chemotherapy were discarded as an aspirant for the future of cancer management long back ago. The arrival of modern cancer treatment modalities like immunotherapy and targeted therapy revolutionized the outlook of the future of cancer management. Amongst both of the modern therapies, targeted therapies have shown an impressive growth in a very short duration of time. The targeted therapies developed rapidly and gained much importance in the global market for cancer therapeutics due to their advantages over the conventional therapies. Targeted therapies are safer and more efficient approach for managing cancer. The only drawback for targeted therapies was that only a few targets were available for developing cancer therapeutics. The high efficacy of targeted therapeutics for cancer raised the demand for identifying new targets.
The worldwide market for Cancer Janus Kinase Inhibitors is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
This report focuses on the Cancer Janus Kinase Inhibitors in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
- Abbott Laboratories
- Asana Biosciences
- Astra Zeneca
- Celon Pharmaceuticals
- Dynamic Pharma
- Eli Lilly
- Gilead Sciences
- Hanmi Pharmaceuticals
- Incyte
- Kyowa Hakko
- Moleculin
- Pfizer
- PIQUR Therapeutics
- Portola Pharmaceuticals
- S-BIO
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Ruxolitinib
- Momelotinib
- Lestaurtinib
- Pacritinib
Market Segment by Applications, can be divided into
- Hospitals
- Ambulatory Surgical Centers
- Others
There are 15 Chapters to deeply display the global Cancer Janus Kinase Inhibitors market.
Chapter 1, to describe Cancer Janus Kinase Inhibitors Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Cancer Janus Kinase Inhibitors, with sales, revenue, and price of Cancer Janus Kinase Inhibitors, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Cancer Janus Kinase Inhibitors, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Cancer Janus Kinase Inhibitors market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Cancer Janus Kinase Inhibitors sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source